A groundbreaking partnership between Corstasis Therapeutics and Cardiovascular Logistics (CVL) is set to revolutionize outpatient heart failure care with ENBUMYST™, a nasal spray diuretic. This collaboration aims to enhance access to non-oral diuretic therapy, offering a new self-administered option for patients.
The Future of Heart Failure Management
Corstasis Therapeutics, a biopharmaceutical company specializing in cardiovascular and renal therapies, has joined forces with CVL, a leading cardiovascular platform, to integrate ENBUMYST™ into modern heart failure treatment pathways. This initiative is a significant step towards improving patient outcomes and access to value-based cardiovascular care.
Expanding Access, Enhancing Care
The partnership will focus on CVL's extensive network of top cardiovascular practices, aiming to provide easier access to diuretic therapy for patients. Ben Esque, CEO of Corstasis Therapeutics, emphasizes the importance of this collaboration, stating, "ENBUMYST gives clinicians a powerful tool for decongestion outside the hospital. By working with CVL, we can directly support physicians who are driving the future of cardiovascular care."
CVL's Chief Medical Officer, Craig Walker, MD, adds, "Our mission is to enable physicians to deliver proactive, efficient care that puts patients first. ENBUMYST aligns perfectly with our vision and FDA-approved care models, offering a more comfortable and accessible treatment option."
A First-of-Its-Kind Initiative
The U.S. Food and Drug Administration (FDA) recently approved ENBUMYST for treating edema associated with heart failure, hepatic disease, and renal conditions. The Corstasis-CVL collaboration is one of the first national efforts to implement a nasal-delivered loop diuretic across outpatient cardiology networks.
ENBUMYST™: A Powerful Diuretic
ENBUMYST (bumetanide nasal spray) is a loop diuretic specifically indicated for treating edema in adults with heart failure, liver disease, and kidney conditions, including nephrotic syndrome. It offers a unique, self-administered approach to decongestion, providing an alternative to traditional oral diuretics.
Important Safety Information
ENBUMYST is contraindicated for patients with anuria, hepatic coma, or a history of hypersensitivity to bumetanide. As a diuretic, it can cause fluid and electrolyte imbalances, leading to potential dehydration and an increased risk of blood clots. Elderly patients, those on higher doses, or with inadequate electrolyte intake are at higher risk for these abnormalities.
If severe progressive renal disease is suspected during treatment, bumetanide should be discontinued. Ototoxicity, though rare at recommended doses, is a potential risk with intravenous therapy, especially at high doses and with impaired renal function.
ENBUMYST should be avoided in patients with significant nasal abnormalities or congestion due to acute rhinitis or other causes. Lactating women treated with ENBUMYST should monitor their infants for excessive urine output, dehydration, and lethargy.
The most common adverse reactions include hypovolemia, headache, muscle cramps, dizziness, hypotension, nausea, and encephalopathy in patients with pre-existing liver disease.
For a comprehensive list of side effects and important safety information, please refer to the full Prescribing Information for ENBUMYST.
About Corstasis Therapeutics
Corstasis Therapeutics is a commercial-stage biopharmaceutical company dedicated to transforming fluid overload management in patients with heart, liver, and kidney diseases. Its lead product, ENBUMYST™, was approved by the FDA on September 12, 2025. For more information, visit www.corstasis.com.
About Cardiovascular Logistics
Cardiovascular Logistics is a physician-led platform partnering with top independent practices to enhance access, optimize outcomes, and improve efficiency in cardiovascular care. CVL provides affiliated practices with administrative, operational, and clinical support, allowing physicians to focus on delivering exceptional patient care. Learn more at https://cvlhealth.com.
This partnership between Corstasis Therapeutics and Cardiovascular Logistics represents a significant advancement in outpatient heart failure management, offering a new, patient-centric approach to care.
Thoughts? Join the discussion in the comments and share your perspective on this innovative collaboration!
